Li Heng, Xiong Wenjie, Liu Huimin, Yi Shuhua, Yu Zhen, Liu Wei, Lyu Rui, Wang Tingyu, Zou Dehui, Li Zengjun, Qiu Lugui
State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.
Chin J Cancer Res. 2017 Apr;29(2):156-165. doi: 10.21147/j.issn.1000-9604.2017.02.09.
This study aims to evaluate the natural history of patients with chronic lymphocytic leukemia (CLL) and a 17p deletion (17p-) and identify the predictive factors within this subgroup.
The sample of patients with CLL were analyzed by fluorescence hybridization for deletions in chromosome bands 11q22, 13q14 and 17p13; trisomy of bands 12q13; and translocation involving band 14q32. The data from 456 patients with or without a 17p- were retrospectively collected and analyzed.
The overall response rate (ORR) in patients with a 17p- was 56.9%, and patients with a high percentage of 17p- (defined as more than 25% of cells harbouring a 17p-) had a lower ORR. The median overall survival (OS) in patients with a 17p- was 78.0 months, which was significantly shorter than the OS in patients without this genetic abnormality (median 162.0 months, P<0.001). Within the subgroup with a 17p-, the progression-free survival was significantly shorter in patients at Binet stage B-C and patients with elevated lactate dehydrogenase (LDH), B symptoms, unmutated and a high percentage of 17p-.
These results indicated that patients with a 17p- CLL have a variable prognosis that might be predicted using simple clinical and laboratory characteristics.
本研究旨在评估慢性淋巴细胞白血病(CLL)伴17p缺失(17p-)患者的自然病程,并确定该亚组内的预测因素。
采用荧光杂交技术分析CLL患者样本,检测染色体带11q22、13q14和17p13的缺失;12q13带的三体性;以及涉及14q32带的易位。回顾性收集并分析了456例有或无17p-的患者的数据。
17p-患者的总缓解率(ORR)为56.9%,17p-比例高(定义为携带17p-的细胞超过25%)的患者ORR较低。17p-患者的中位总生存期(OS)为78.0个月,显著短于无此基因异常患者的OS(中位162.0个月,P<0.001)。在17p-亚组中,Binet分期为B-C期、乳酸脱氢酶(LDH)升高、有B症状、未突变且17p-比例高的患者无进展生存期显著缩短。
这些结果表明,17p-CLL患者的预后各不相同,可通过简单的临床和实验室特征进行预测。